Arvinas to Present at Upcoming Conferences
Arvinas, a clinical-stage biotechnology company, will present at two key conferences in November 2022. At the Society for Neuroscience Annual Meeting, Angela Cacace will showcase research on PROTAC® molecules targeting neurodegenerative proteins on November 12. Additionally, Arvinas will participate in the Stifel Healthcare Conference with Ron Peck and Randy Teel engaging in a fireside chat on November 15. The company focuses on innovative therapies that degrade disease-causing proteins, currently advancing multiple clinical-stage programs, including treatments for prostate and breast cancer.
- None.
- None.
Insights
Analyzing...
NEW HAVEN, Conn., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming conferences:
- Society for Neuroscience (SFN) Annual Meeting: Saturday, November 12, 4:00-5:00 p.m. PT. Angela Cacace, Ph.D., Senior Vice President of Neuroscience and Platform Biology, will deliver a poster presentation titled, “Orally Administered PROTAC® Molecules Selectively Clear Pathologic Neurodegenerative Proteins in CNS & Muscle.”
- Stifel Healthcare Conference: Tuesday, November 15 at 11:30 a.m. ET. Ron Peck, M.D., Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events & Presentations section of the Investors & Media section of the Company’s website.
About Arvinas
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs: bavdegalutamide (ARV-110) and ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
When will Arvinas participate in the Society for Neuroscience Annual Meeting?
What will be presented by Arvinas at the Society for Neuroscience Annual Meeting?
When is the Stifel Healthcare Conference where Arvinas will speak?
Who will represent Arvinas at the Stifel Healthcare Conference?
What is the focus of Arvinas' research and development?
